Activated CD4+ T-lymphocyte (Activated CD4+ T-cell)

Activated CD4+ T-lymphocytes, also known as helper T-cells, are a critical component of the adaptive immune system that coordinate the body's response to pathogens. Activation occurs when the T-cell receptor (TCR) recognizes a specific antigen presented by major histocompatibility complex (MHC) class II molecules on antigen-presenting cells, supplemented by costimulatory signals (StatPearls, 2023). Once activated, these cells proliferate and differentiate into specialized subsets like Th1, Th2, or Th17, which secrete cytokines to direct the activity of other immune cells such as B-lymphocytes and cytotoxic T-cells (NIH, 2022). In many diseases, including rheumatoid arthritis and multiple sclerosis, these cells are inappropriately activated against self-antigens, leading to chronic inflammation and tissue damage (Nature Reviews Immunology, 2021). Consequently, they are a major focus of immunosuppressive therapy, where drugs like calcineurin inhibitors or monoclonal antibodies are used to disrupt their activation or effector functions to treat autoimmunity and prevent organ transplant rejection (PubMed, 2020). These cells also serve as the primary host for the Human Immunodeficiency Virus (HIV), which leads to their depletion and the subsequent development of AIDS (NIH, 2022). Monitoring activation markers like CD25 and CD69 on these cells is essential for assessing immune status and the efficacy of immunomodulatory treatments (UniProt, 2023).

Other names

Activated helper T-cellCD4+ effector T-cellAntigen-stimulated CD4+ T-lymphocyteEffector CD4+ T-cell

Drugs typically target activated CD4+ T-lymphocytes by inhibiting intracellular signaling pathways such as calcineurin inhibition (e.g., Cyclosporine), blocking essential growth factor receptors like the IL-2 receptor (e.g., Basiliximab), or preventing necessary costimulatory signals like the CD28-B7 interaction (e.g., Abatacept) required for full activation and proliferation (PubChem, 2023; PubMed, 2020).